The association between PD-L1 expression and the clinical outcomes to vascular endothelial growth factor-targeted therapy in patients with metastatic clear cell renal cell carcinoma

Oncologist

Volumn 20, Issue 11, 2015, Pages 1253-1260

  Shin, Su Jin ^a   Jeon, Yoon Kyung ^b   Cho, Yong Mee ^a   Lee, Jae Lyun ^a   Chung, Doo Hyun ^b,c   Park, Ji Young ^d   Go, Heounjeong ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Kyungpook National University School of Medicine   (South Korea)

Author keywords

Metastatic clear cell renal cell carcinoma; Prognosis; Programmed death ligand 1; Programmed death ligand 2; Responsiveness; Vascular endothelial growth factor pathway tyrosine kinase inhibitor

Indexed keywords

PAZOPANIB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; SORAFENIB; SUNITINIB; VASCULOTROPIN; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PDCD1LG2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TUMOR MARKER; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCORING SYSTEM; TUMOR NECROSIS; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA, RENAL CELL; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84946555727     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0151     Document Type: Article

References (28)

1. Srinivasan R, Ricketts CJ, Sourbier C et al. New strategies in renal cell carcinoma: Targeting the genetic and metabolic basis of disease. Clin Cancer Res 2015;21:100-17.
2. Rini BI. Vascular endothelial growth factor-targetedtherapy in metastatic renal cell carcinoma. Cancer 2009;115(Suppl):2306-2312.
3. Escudier B, Eisen T, Porta C et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii65-vii71.
4. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010;28:1061-1068.
5. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;373:1119-1132.
6. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
7. Di Lorenzo G, Porta C, BellmuntJ et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 2011;59:526-540.
8. Maroto P, Rini B. Molecular biomarkers in advanced renal cell carcinoma. Clin Cancer Res 2014;20:2060-2071.
9. Park JY, Lee JL, Baek S et al. Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy. Hum Pathol 2014;45:1437-1444.
10. Beuselinck B, Job S, Becht E et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin Cancer Res 2015;21: 1329-1339.
11. Thompson RH, Dong H, Kwon ED. Implications of b7-h1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 2007;13:709s-715s.
12. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366: 2455-2465.
13. Motzer RJ, Rini BI, McDermott DF et al. Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. J Clin Oncol 2015;33:1430-1437.
14. Garon EB, Rizvi NA, Hui Retal. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-2028.
15. Eble JNEJ, Sesterhenn IA. World Health Organization Classification of Tumors. Lyon, France: IARC Press, 2004.
16. Delahunt B, Cheville JC, Martignoni G et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 2013;37: 1490-1504.
17. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECISTguideline (version 1.1). Eur J Cancer 2009;45:228-247.
18. Figueroa DJ, Liu Y, Gagnon RC et al. Correlation of PDL1 tumor expression and outcomes in renal cell carcinoma (RCC) patients (pts) treated with pazopanib (paz). J Clin Oncol 2013;31:3021a.
19. Choueiri TK, Figueroa DJ, Fay AP et al. Correlation of pd-l1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: Results from comparz, a randomized controlled trial. Clin Cancer Res 2015;21:1071-1077.
20. Olson OC, Joyce JA. Microenvironment-mediated resistance to anticancer therapies. Cell Res 2013;23: 179-181.
21. Heine A, Held SA, Bringmann A et al. Immuno-modulatory effects of anti-angiogenic drugs. Leukemia 2011;25:899-905.
22. Hugonnet F, Fournier L, Medioni J et al. Metastatic renal cell carcinoma: Relationship between initial metastasis hypoxia, change after 1 month’s sunitinib, and therapeutic response: An 18F-fluoromisonidazole PET/CT study. J Nucl Med 2011;52:1048-1055.
23. Francisco LM, Salinas VH, Brown KE et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009;206:3015-3029.
24. Barsoum IB, Smallwood CA, Siemens DR et al. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res 2014;74:665-674.
25. Amin A, Plimack ER, Infante JR et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol 2014;32:5010a.
26. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-264.
27. Rozali EN, Hato SV, Robinson BW et al. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012; 2012:656340.
28. Ghiotto M, Gauthier L, Serriari N et al. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int Immunol 2010;22: 651-660.